Gli altri portali
Notizie a Confronto
Comunicati Stampa
Social News
Offerte di Lavoro
Comunicati Stampa
Sezioni
Toggle navigation
Prima pagina
Elenco
Nuovo account
Inserimento
Pannello di controllo
Modifica password
Salute e Benessere
Seleziona Categoria
Tutte le Categorie
Agricoltura
Ambiente
Arte e Cultura
Cibi e Bevande
Economia
Editoria e Media
Elettronica
Energia
Fiere ed Eventi
Industria
Information Technology
Internet
Istruzione e Formazione
Moda
Non Profit
Politica e Istituzioni
Salute e Benessere
Scienza e Tecnologia
Servizi
Società
Spettacolo
Sport
Telecomunicazioni
Trasporti
Turismo
Varie
Italiano
Inglese
Spagnolo
Inventiva announces the positive recommendation of the fourth DMC of the NATiV3…
The Data Monitoring Committee recommended to continue the clinical trial without modification of the current protocol, based on the pre-planned review of safety data.The recommendation was based on the unblinded review by the DMC of safety data from more than 900 patients randomized in the main and exploratory cohorts, including more than 360 and 80 patients that have been treated for more than 48 and 72 weeks, respectively.The patient who experienced the adverse event of increased liver...
Nasdaq GlobeNewswire
16/05/2024
The US Garden Hand Tools Market to Reach $3.80 Billion by 2029 - Southern Region…
Browse in-depth TOC on the US Garden Hand Tools Market125 – Tables 85 – Figures 296 – Pages Browse in-depth TOC on the US Garden Hand Tools Market125 – Tables 85 – Figures 296 – Pages The U.S. Garden Hand Tools Market Report Scope The US garden hand tool industry is heading toward sophistication and customization of products to keep ahead of the other players in the market. Technological advances and the use of battery-driven tools...
PR Newswire
16/05/2024
Glutamine Sales Set to Total USD 199 Million by 2034 Amid Growing Health and…
Sales remain particularly high for L-glutamine owing to its perceived health benefits. The target segment accounted for a revenue share of 63% in 2023 and is set to experience steady growth through 2034. Sales remain particularly high for L-glutamine owing to its perceived health benefits. The target segment accounted for a revenue share of63%in 2023 and is set to experience steady growth through 2034. Download the Sample PDF report to explore key market insights and trends:...
PR Newswire
16/05/2024
The US Emergency Medical Services (EMS) Market to Reach $26.20 Billion by 2029…
To Know More, Click: https://www.focusreports.store/report/us-emergency-medical-services-market To Know More, Click:https://www.focusreports.store/report/us-emergency-medical-services-market The US Emergency Medical Services (EMS) Market Report Scope The demand for emergency medical services is rising due to multiple factors, including the rising number of baby boomers, the growing aging population, the increase in healthcare expenditure, and rising road accidents. The US is the...
PR Newswire
16/05/2024
Radiopharmaceutical CDMO/CMO Services Market to Reach USD 5.44 Billion by 2031 -…
Radiopharmaceuticals, which contain radioactive isotopes, are crucial in nuclear medicine for both diagnostic imaging and therapeutic purposes. These drugs emit radiation that medical imaging devices can detect, aiding in visualizing and diagnosing various medical conditions. Radiopharmaceuticals, which contain radioactive isotopes, are crucial in nuclear medicine for both diagnostic imaging and therapeutic purposes. These drugs emit radiation that medical imaging devices can detect, aiding…
PR Newswire
16/05/2024
Oxurion Receives Transparency Notification from Atlas Special Opportunities…
Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC Leuven, BELGIUM – May 16, 2024 – 07:00 PM CET(Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, today announced that, pursuant to Belgian Transparency legislation 1it has received a transparency notification as follows: Oxurion received a transparency notification on May 16, 2024, from Atlas Special Opportunities, LLC indicating that as of May 13, 2024, it held 1,000,850,000...
Nasdaq GlobeNewswire
16/05/2024
BioVaxys Technology Corp. Announces Failure to File Cease Trade Order
The OSC had previously granted, on February 29, 2024, a management cease trade order, which has been been revoked and replaced by the FFCTO dated May 15, 2024. The OSC had previously granted, onFebruary 29, 2024, a management cease trade order, which has been been revoked and replaced by the FFCTO datedMay 15, 2024. The Company is working diligently to facilitate the completion of the Required Annual Filings and the Required Interim Filings and expects to be in a position to file in...
PR Newswire
16/05/2024
King Faisal Specialist Hospital & Research Centre Wins 2024 Tech Impact Award…
RIYADH, Saudi Arabia, May16, 2024(GLOBE NEWSWIRE) -- King Faisal Specialist Hospital & Research Centre (KFSHRC) has achieved a significant milestone by winning the 2024 Tech Impact Award, a prestigious recognition presented by the Value-Based Health Care Centre Europe. This accolade, awarded for its pioneering Home Hemodialysis (HHD) initiative, underscores KFSHRC's unwavering commitment to comprehensive healthcare and further cement its position as a global leader in the...
Nasdaq GlobeNewswire
16/05/2024
Circle Cardiovascular Imaging Partners with inHEART to Distribute AI-Driven…
Circle Cardiovascular Imaging (CVI) is known for its multi-modal AI-based solutions that streamline cardiac imaging and reporting workflows across the cardiac service line, including coronary artery disease, heart failure, and structural heart disease. The Circle cvi42 platform offers easy-to-use, clinically validated tools that integrate seamlessly into existing clinical workflows to aid clinicians with quantification of cardiac function and flow, visualization of tissue abnormalities…
PR Newswire
16/05/2024
Lab Automation Market to be Worth $11.31 Billion by 2031 - Exclusive Report by…
Lab automation refers to the use of automated systems, instruments, and software to streamline and optimize various laboratory processes and tasks. It involves the deployment of automated systems and technologies that are intended to enhance efficiency and accuracy in laboratory processes. Lab automation refers to the use of automated systems, instruments, and software to streamline and optimize various laboratory processes and tasks. It involves the deployment of automated systems and...
PR Newswire
16/05/2024
Newborn Screening Market to be Worth $2.69 Billion by 2031 - Exclusive Report by…
Newborn screening is a screening program for infants under which pre-symptomatic congenital conditions are detected so that treatment can be commenced as soon as possible to prevent or reduce the long-term consequences of the disease. These programs are usually run by the national or state governing bodies with the aim of screening all infants for a defined panel of disorders that are treatable. These tests include hearing, blood, pulse oximetry, and other similar tests and benefit the newborn…
PR Newswire
16/05/2024
Peripheral Artery Disease Market to Reach $10.8 billion, Globally, by 2035 at…
Prime determinants of growth Prime determinants of growth The peripheral artery disease market is expected to grow significantly owing to rise in the prevalence of peripheral artery disease, surge in the geriatric population, and rise in the adoption of minimal invasive procedures. Furthermore, technological advancement in peripheral artery disease treatment devices is expected to present significant growth opportunities in the peripheral artery disease market. Report coverage &...
PR Newswire
16/05/2024
Drug Screening Market Worth $19.5 billion | MarketsandMarkets™
Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=162987773 Download an Illustrative overview:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=162987773 Browse in-depth TOC on "Drug Screening Market" 740 - Tables 62 - Figures 533 - Pages Drug Screening Market Scope: Services segment is expected to grow at the highest CAGR during the forecast period in 2024. On the basis of product & service segment, the drug...
PR Newswire
16/05/2024
Seegene and Springer Nature Announce Strategic Alliance
SEOUL, South Korea, May 16, 2024 /PRNewswire/ -- Seegene Inc. (KQ096530), a leading South Korean company providing a total solution for PCR molecular diagnostics, announced on May 16th the signing of a strategic alliance agreement with Springer Nature, the publisher of the prestigious scientific journal, Nature. SEOUL, South Korea , May 16, 2024 /PRNewswire/ -- Seegene Inc. (KQ096530), a leading South Korean company providing a total solution for PCR molecular diagnostics, announced on...
PR Newswire
16/05/2024
Brainomix Announces New Studies Further Validating the Impact of Brainomix 360…
Dr Michalis Papadakis, CEO and Co-Founder of Brainomix, said: "The studies presented this week at ESOC reflect our ongoing commitment to scientific excellence and our extensive academic collaborations with world-class research institutions, including the Mayo Clinic, the Rockefeller Institute at West Virginia University, and Boston Medical Center. These studies provide further validation that our AI-enabled technology can play a critical role in stroke care, helping clinicians make more…
PR Newswire
16/05/2024
Notification of managers' transactions
ANNOUNCEMENT NO. 267 Notification of managers' transactions ChemoMetec A/S has received the enclosed notification pursuant to Article 19 of EU Regulation no. 596/2014 of transactions related to shares in ChemoMetec A/S made by persons discharging managerial responsibilities in ChemoMetec A/S and/or persons closely associated with them.See the transactions of CFO Niels Høy Nielsen in the attached PDF document. For further information, please contact:Niels Høy Nielsen, CFO...
Nasdaq GlobeNewswire
16/05/2024
Akari Therapeutics Reports First Quarter 2024 Financial Results and Recent…
Entered into a Definitive Merger Agreement with Peak Bio; Expected to Close in the Third Quarter of 2024 Samir R. Patel, M.D. Appointed Interim CEOPlan for Prioritization of Peak Bio's ADC Cancer Therapeutic Platform Technology and Akari's PAS-nomacopan for Geographic Atrophy Implementation of Restructuring Plan to Reduce Operating Costs Existing Investors Support the Company with Issuance of $1 million in Unsecured Convertible Notes BOSTON and LONDON, May16,...
Nasdaq GlobeNewswire
16/05/2024
MoonLake Immunotherapeutics starts Phase 3 VELA program of the Nanobody®…
MoonLake Immunotherapeutics starts Phase 3 VELA program of the Nanobody® sonelokimab in patients with moderate-to-severe hidradenitis suppurativa VELA is the first Phase 3 program in hidradenitis suppurativa to use the higher clinical response level of HiSCR75 as the primary endpointThe topline primary endpoint readout at week 16, together with data on other endpoints, is expected as of mid-2025Program will evaluate sonelokimab for a total of 52 weeks, across VELA-1 and...
Nasdaq GlobeNewswire
16/05/2024
Biogen and Ionis Announce Topline Phase 1/2 Study Results of Investigational…
Development of BIIB105, an investigational antisense oligonucleotide for amyotrophic lateral sclerosis (ALS), will be discontinued based on data from the Phase 1/2 ALSpire studyBiogen and Ionis continue their long-standing commitment to developing therapies for ALS given the devastating impact of this progressive, fatal neurodegenerative condition CAMBRIDGE, Mass. and CARLSBAD, Calif., May16, 2024(GLOBE NEWSWIRE) --BiogenInc. (Nasdaq: BIIB) andIonis Pharmaceuticals, Inc...
Nasdaq GlobeNewswire
16/05/2024
Oncolytics Biotech® Announces Voting Results from the Annual General Meeting of…
In addition to the election of all nominees listed as directors in the management information circular, dated March 24, 2024, Oncolytics shareholders approved all other resolutions placed before the meeting. These included fixing the number of directors of the Corporation for the ensuing year at eight and appointing the auditors for the Corporation for the ensuing year. In addition to the election of all nominees listed as directors in the management information circular, datedMarch 24,...
PR Newswire
16/05/2024
M42 receives Global Healthcare Accreditation Certification for Excellence in…
Since its inception, M42 has attracted patients from countries across the globe, including the UK, the US, Kuwait, India and Saudi Arabia. M42 leads the way in advanced medical procedures with state-of-the-art facilities such as Cleveland Clinic Abu Dhabi, Healthpoint, Moorfields and Imperial College London Diabetes Centre, among others. From robotic orthopedics to bariatric surgery, transplants, cardiac interventions, and IVF, M42 sets the standard for premier medical care globally. M42 now…
PR Newswire
16/05/2024
Novartis meets all tender offer conditions to acquire MorphoSys AG for EUR 68…
Novartis secured 79.6 percent acceptance by MorphoSys shareholders during the initial acceptance period, reaching the minimum 65% acceptance thresholdSettlement of the shares tendered during the initial acceptance period is expected to occur on 23 May 2024Additional statutory acceptance period is expected to end on 30 May 2024 at 24:00 hours CESTTransaction strengthens the Novartis pipeline in oncology, adding pelabresib, a late-stage BET inhibitor for myelofibrosis and...
Nasdaq GlobeNewswire
16/05/2024
Coloplast A/S - Invitation to Coloplast's Meet the Management event on 6 June…
The event will take place on Thursday, 6 June 2024 at Coloplast's Headquarters Holtedam 3, 3050 Humlebaek, Denmark from 11.30 - 18.00 CEST (Central European Summer Time) Coloplast invites institutional investors, equity analysts and media to attend our 2024 Meet the Management event. The event will be held in person at our headquarters in Humlebaek, Denmark, with the option to join us virtually for the plenary session. The purpose of the event is to provide participants with the...
Nasdaq GlobeNewswire
16/05/2024
Novo Nordisk Foundation, Rigshospitalet and CNIC press release: One in three…
"Atherosclerosis may develop from an early age and often remains 'silent', that is, without symptoms, for many years until it suddenly hits, for example with a heart attack," says Dr. Henning Bundgaard, Chief Physician and Professor at the Department of Cardiology at Rigshospitalet, Copenhagen, Denmark, and leader of the project. "In REACT, we hope to identify new means to detect atherosclerosis at earlier stages and at a younger age, that is during the 'silent' period."…
PR Newswire
16/05/2024
Altri Comunicati